Читать книгу Protocols for High-Risk Pregnancies - Группа авторов - Страница 102

1 Deka D, Dadhwal V, Sharma AK, et al. Perinatal survival and procedure‐related complications after intrauterine transfusion for red cell alloimmunization. Arch Gynecol Obstet 2016; 293(5):967–73.

2  Dodd JM, Windrim RC, van Kamp I. Techniques of intrauterine fetal transfusion for women with red‐cell alloimmunization for improving health outcomes. Cochrane Database Syst Rev 2012;( 9):CD007096.

3 Hellmund A, Geipel A, Berg C, et al. Early intrauterine transfusion in fetuses with severe anemia caused by parvovirus B19 infection. Fetal Diagn Ther 2018; 43(2):129–37.

4 Lindenburg ITM, Smits‐Wintjens VE, van Klink JM, et al. Long‐term neuro‐developmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol 2012; 206:141.e1–148.e8.

5 Lindenburg ITM, van Kamp I, Oepkes D. Intrauterine blood transfusion: current indications and associated risks. Fetal Diagn Ther 2014; 36:263–71.

6 Ruma MS, Moise KJ Jr, Kim E, et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol 2007; 196;138.e1–138.e6.

7 Wallace AH, Dalziel SR, Cowan BR, et al. Long‐term cardiovascular outcome following fetal anaemia and intrauterine transfusion: a cohort study. Arch Dis Child 2017; 102(1):40–5.

8 Zwiers C, Lindenburg ITM, Klumper FJ, et al. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol 2017; 50:180–6.

9 Zwiers C, van der Bom JG, van Kamp I, et al. Postponing Early Intrauterine Transfusion with Intravenous immunoglobulin Treatment: the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 2018; 219:291.e1–9.

10 Zwiers C, van Kamp I, Oepkes D, Lopriore E. Intrauterine transfusion and non‐invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Exp Rev Hematol 2017; 10(4):337–44.